Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Chemosphere ; 313: 137483, 2023 Feb.
Article in English | MEDLINE | ID: mdl-36513201

ABSTRACT

Nanostructured materials offer a significant role in wastewater treatment with diminished capital and operational expense, low dose, and pollutant selectivity. Specifically, the nanocomposites of cellulose with inorganic nanoparticles (NPs) have drawn a prodigious interest because of the extraordinary cellulose properties, high specific surface area, and pollutant selectivity of NPs. Integrating inorganic NPs with cellulose biopolymers for wastewater treatment is a promising advantage for inorganic NPs, such as colloidal stability, agglomeration prevention, and easy isolation of magnetic material after use. This article presents a comprehensive overview of water treatment approaches following wastewater remediation by green and environmentally friendly cellulose/inorganic nanoparticles-based bio-nanocomposites. The functionalization of cellulose, functionalization mechanism, and engineered hybrid materials were thoroughly discussed. Moreover, we also highlighted the purification of wastewater through the composites of cellulose/inorganic nanoparticles via adsorption, photocatalytic and antibacterial approach.


Subject(s)
Environmental Pollutants , Nanocomposites , Nanoparticles , Water Pollutants, Chemical , Water Purification , Wastewater , Cellulose
2.
Medicine (Baltimore) ; 100(25): e26496, 2021 Jun 25.
Article in English | MEDLINE | ID: mdl-34160464

ABSTRACT

ABSTRACT: Esophageal cancer (EC) is relatively common; at the time of diagnosis, 50% of cases present with distant metastases, and most patients are men. This study aimed to examine and compare the clinicopathological characteristics and metastatic patterns of male EC (MEC) and female EC (FEC). In addition, risk factors associated with MEC prognosis were evaluated.The present study population was extracted from the Surveillance Epidemiology and End Results database. MEC characteristics and factors associated with prognosis were evaluated using descriptive analysis, the Kaplan-Meier method, and the Cox regression model.A total of 12,558 MEC cases were included; among them, 3454 cases had distant organ metastases. Overall, 27.5% of the entire cohort were patients with distant organ metastases. Compared with patients with non-metastatic MEC, patients with metastatic MEC were more likely to be aged ≤60 years, of Black and White race, have a primary lesion in the overlapping esophagus segments, and have a diagnosis of adenocarcinoma of poorly differentiated and undifferentiated grade that was treated with radiotherapy and chemotherapy rather than surgery; moreover, they were also more likely to be married and insured. In addition, patients with MEC were more likely to be aged ≤60 years, White race, and diagnosed with a primary lesion in the lower third of the esophagus and overlapping esophagus segments, and treated without chemotherapy, compared with those with FEC. Patients in the former group were also more likely than those in the latter group to be unmarried and have bone metastasis only and lung metastasis only. Liver, lung, and bone metastases separately, and simultaneous liver and lung metastases were associated with poor survival in MEC patients.Metastatic MEC is associated with clinicopathological characteristics and metastatic patterns different from those associated with non-metastatic MEC and metastatic FEC. Metastatic MEC and FEC patients may have similar prognoses. Distant organ metastasis may be associated with poor prognosis in patients with MEC and FEC.


Subject(s)
Bone Neoplasms/epidemiology , Brain Neoplasms/epidemiology , Esophageal Neoplasms/pathology , Liver Neoplasms/epidemiology , Lung Neoplasms/epidemiology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Bone Neoplasms/secondary , Bone Neoplasms/therapy , Brain Neoplasms/secondary , Brain Neoplasms/therapy , Chemoradiotherapy/statistics & numerical data , Esophageal Neoplasms/mortality , Esophageal Neoplasms/secondary , Esophageal Neoplasms/therapy , Esophagectomy/statistics & numerical data , Esophagus , Female , Humans , Kaplan-Meier Estimate , Liver Neoplasms/secondary , Liver Neoplasms/therapy , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Male , Marital Status/statistics & numerical data , Middle Aged , Prognosis , Retrospective Studies , Risk Factors , SEER Program/statistics & numerical data , Sex Factors , Young Adult
3.
Front Oncol ; 11: 603953, 2021.
Article in English | MEDLINE | ID: mdl-33718154

ABSTRACT

BACKGROUND: Esophageal cancer is one of the most common cancer types, with its most common distant metastatic site being the lung. Currently, population-based data regarding the proportion and prognosis of patients with esophageal cancer with lung metastases (ECLM) at the time of diagnosis is insufficient. Therefore, we aimed to determine the proportion of patients with ECLM at diagnosis, as well as to investigate the prognostic parameters of ECLM. METHODS: This population-based observational study obtained data from the Surveillance, Epidemiology, and End Results (SEER) database registered between 2010 and 2016. Multivariable logistic regression was performed to identify predictors of the presence of ECLM at diagnosis. Multivariable Cox regression and competing risk analysis were used to assess prognostic factors in patients with ECLM. Median survival was estimated using Kaplan-Meier curves. RESULTS: Of 10,965 patients diagnosed with esophageal cancer between 2010 and 2016, 713 (6.50%) presented with initial lung metastasis at diagnosis. Lung metastasis represented 27.15% of all cases with metastatic disease to any distant site. Considering all patients with esophageal cancer, multivariable logistic regression indicated that pathology grade, pathology type, T staging, N staging, race, and number of extrapulmonary metastatic sites were predictive factors for the occurrence of lung metastases at diagnosis. The median survival time of patients with ECLM was 4.0 months. Patients receiving chemotherapy or chemoradiotherapy had the longest median overall survival, 7.0 months. Multivariable Cox regression indicated that age, histology type, T2 staging, number of extrapulmonary metastatic sites, and treatment (chemotherapy, radiotherapy, or chemoradiotherapy) were independent predictors for overall survival (OS). Multivariable competing risk analysis determined that age, number of extrapulmonary metastatic sites, and treatment were independent predictors for esophageal cancer-specific survival (CSS). CONCLUSION: The findings of this study may provide important information for the early diagnosis of ECLM, as well as aid physicians in choosing appropriate treatment regimens for these patients.

4.
Sci Rep ; 8(1): 15341, 2018 10 26.
Article in English | MEDLINE | ID: mdl-30367075

ABSTRACT

In low-income countries of the Horn of Africa, pulmonary infections are usually considered as tuberculosis, which diagnosis relies on clinical data and positive microscopic observation. This strategy allows non-tuberculous mycobacteria to escape detection, facilitating their emergence in populations. A non-tuberculous mycobacterium strain FB-527 was unexpectedly cultured from the sputum of a Djiboutian patient otherwise diagnosed with multi-drug resistant (MDR) tuberculosis. The sequencing of the rpoB and 16S rRNA genes showed that the isolate was identical to strain FI-09026 previously named "Mycobacterium simulans" and reported only once from a Somali patient. Strain FB-527 mimicked Mycobacterium tuberculosis colonies and enzymatic profile using API ZYM strip and was in vitro resistant to rifampicin and isoniazid. Isolation of two MDR mycobacteria complicated the diagnosis and therapeutic management of the patient. We here report on the complete description of strain FB-527 and strain FI-09026 including genome sequencing, finalizing the description of the proposed new species "Mycobacterium simulans".


Subject(s)
Drug Resistance, Multiple, Bacterial/genetics , Mycobacterium tuberculosis/isolation & purification , Nontuberculous Mycobacteria/isolation & purification , Tuberculosis, Multidrug-Resistant/diagnosis , Adult , Africa , Antitubercular Agents/pharmacology , Bacterial Proteins/chemistry , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Humans , Isoniazid/pharmacology , Male , Microbial Sensitivity Tests , Mycobacterium tuberculosis/classification , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/genetics , Nontuberculous Mycobacteria/classification , Nontuberculous Mycobacteria/drug effects , Nontuberculous Mycobacteria/genetics , Phenotype , Phylogeny , RNA, Ribosomal, 16S/chemistry , RNA, Ribosomal, 16S/metabolism , Rifampin/pharmacology , Sputum/microbiology , Tuberculosis, Multidrug-Resistant/microbiology
5.
Int J Antimicrob Agents ; 51(2): 235-238, 2018 Feb.
Article in English | MEDLINE | ID: mdl-28711677

ABSTRACT

In the Horn of Africa, there is a high prevalence of tuberculosis that is reported to be partly driven by multidrug-resistant (MDR) Mycobacterium tuberculosis strictu sensu strains. We conducted a prospective study to investigate M. tuberculosis complex species causing tuberculosis in Djibouti, and their in vitro susceptibility to standard anti-tuberculous antibiotics in addition to clofazimine, minocycline, chloramphenicol and sulfadiazine. Among the 118 mycobacteria isolates from 118 successive patients with suspected pulmonary tuberculosis, 111 strains of M. tuberculosis, five Mycobacterium canettii, one 'Mycobacterium simulans' and one Mycobacterium kansasii were identified. Drug-susceptibility tests performed on the first 78 isolates yielded nine MDR M. tuberculosis isolates. All isolates were fully susceptible to clofazimine, minocycline and chloramphenicol, and 75 of 78 isolates were susceptible to sulfadiazine. In the Horn of Africa, patients with confirmed pulmonary tuberculosis caused by an in vitro susceptible strain may benefit from anti-leprosy drugs, sulfamides and phenicol antibiotics.


Subject(s)
Antitubercular Agents/therapeutic use , Mycobacterium kansasii/drug effects , Mycobacterium tuberculosis/drug effects , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Pulmonary/drug therapy , Adult , Chloramphenicol/pharmacology , Clofazimine/pharmacology , Djibouti , Female , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Minocycline/pharmacology , Mycobacterium kansasii/isolation & purification , Mycobacterium tuberculosis/classification , Mycobacterium tuberculosis/isolation & purification , Prospective Studies , Sulfadiazine/pharmacology , Tuberculosis, Multidrug-Resistant/microbiology , Tuberculosis, Pulmonary/microbiology
6.
Sci Rep ; 7(1): 17672, 2017 12 15.
Article in English | MEDLINE | ID: mdl-29247181

ABSTRACT

Djibouti is a small country in the Horn of Africa with a high TB incidence (378/100,000 in 2015). Multidrug-resistant TB (MDR-TB) and resistance to second-line agents have been previously identified in the country but the extent of the problem has yet to be quantified. A national survey was conducted to estimate the proportion of MDR-TB among a representative sample of TB patients. Sputum was tested using XpertMTB/RIF and samples positive for MTB and resistant to rifampicin underwent first line phenotypic susceptibility testing. The TB supranational reference laboratory in Milan, Italy, undertook external quality assurance, genotypic testing based on whole genome and targeted-deep sequencing and phylogenetic studies. 301 new and 66 previously treated TB cases were enrolled. MDR-TB was detected in 34 patients: 4.7% of new and 31% of previously treated cases. Resistance to pyrazinamide, aminoglycosides and capreomycin was detected in 68%, 18% and 29% of MDR-TB strains respectively, while resistance to fluoroquinolones was not detected. Cluster analysis identified transmission of MDR-TB as a critical factor fostering drug resistance in the country. Levels of MDR-TB in Djibouti are among the highest on the African continent. High prevalence of resistance to pyrazinamide and second-line injectable agents have important implications for treatment regimens.


Subject(s)
Tuberculosis, Multidrug-Resistant/epidemiology , Tuberculosis, Multidrug-Resistant/genetics , Adolescent , Adult , Africa/epidemiology , Aged , Antitubercular Agents/pharmacology , Child , Child, Preschool , Djibouti/epidemiology , Female , Fluoroquinolones/pharmacology , High-Throughput Nucleotide Sequencing/methods , Humans , Infant , Infant, Newborn , Male , Microbial Sensitivity Tests/methods , Middle Aged , Mycobacterium tuberculosis/drug effects , Phylogeny , Prevalence , Rifampin/pharmacology , Surveys and Questionnaires , Tuberculosis, Multidrug-Resistant/drug therapy , Young Adult
7.
Emerg Infect Dis ; 20(1): 21-8, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24520560

ABSTRACT

"Mycobacterium canettii," an opportunistic human pathogen living in an unknown environmental reservoir, is the progenitor species from which Mycobacterium tuberculosis emerged. Since its discovery in 1969, most of the ≈70 known M. canettii strains were isolated in the Republic of Djibouti, frequently from expatriate children and adults. We show here, by whole-genome sequencing, that most strains collected from February 2010 through March 2013, and associated with 2 outbreaks of lymph node tuberculosis in children, belong to a unique epidemic clone within M. canettii. Evolution of this clone, which has been recovered regularly since 1983, may mimic the birth of M. tuberculosis. Thus, recognizing this organism and identifying its reservoir are clinically important.


Subject(s)
Mycobacterium/classification , Tuberculosis, Lymph Node/epidemiology , Tuberculosis, Lymph Node/microbiology , Adolescent , Adult , Biosynthetic Pathways , Child , Child, Preschool , Cluster Analysis , Clustered Regularly Interspaced Short Palindromic Repeats , Djibouti/epidemiology , Female , Genome, Bacterial , Humans , Infant , Male , Middle Aged , Mycobacterium/genetics , Mycobacterium/metabolism , Phylogeny , Polymorphism, Single Nucleotide , Vitamin B 12/biosynthesis , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...